Trial Profile
A Phase 2b, Multicenter, Randomized, Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naive and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5, and 6 Infection Without Cirrhosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2019
Price :
$35
*
At a glance
- Drugs Adafosbuvir (Primary) ; AL 335/odalasvir/simeprevir (Primary) ; Odalasvir (Primary) ; Simeprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms OMEGA-1
- Sponsors Janssen Research & Development; Janssen-Cilag
- 28 Jan 2019 Results evaluating efficacy and safety of AL-335, odalasvir and simeprevirJNJ-4178 regimen in chronic hepatitis C virus patients published in the Hepatology
- 04 Dec 2017 Status changed from active, no longer recruiting to completed.
- 24 Oct 2017 Results of this and other phase II study assessing virologic response presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.